Motion Capture Quantification of User Variation in Topical Microparticle Application

Motion capture has the potential to shed light on topical drug delivery application. This approach holds promise both as a training tool, and for the development of skin technology, but first, this approach requires validation. Elongated microparticles (EMP) are a physical delivery enhancement technology that relies on a user working in the microparticles using a textured applicator. We used this approach to test the hypothesis that motion capture data can be used to characterize the topical application process. Motion capture was used to record participants while applying a mixture of EMP and sodium fluorescein to ex-vivo porcine skin samples. Treated skin was assessed using reflectance confocal and fluorescence microscopy. Image analysis was used to quantify the microparticle density and the presence of a fluorescent drug surrogate, sodium fluorescein. A strong correlation was present between applicator motion and microparticle and drug delivery profiles. There were quantitative and qualitative differences in the intra- and inter- user application methods that went beyond the level of training. Frequency and velocity of the applicator motion were key factors that correlated with EMP density. Our quantitative analysis of an experimental dermatological device supports the hypothesis that self-application may benefit from some form of digital monitoring or training with feedback. Our conclusion is that the integration of motion capture into experimental dermatological research offers an improved and quantifiable perspective that could be broadly useful with respect to topical applications, and with respect to the instruction provided to patients and clinicians.

[1]  T. Prow,et al.  Physical drug delivery enhancement for aged skin, UV damaged skin and skin cancer: Translation and commercialization. , 2020, Advanced drug delivery reviews.

[2]  Yousuf H. Mohammed,et al.  Advances and controversies in studying sunscreen delivery and toxicity. , 2020, Advanced drug delivery reviews.

[3]  A. Feizpour,et al.  Imaging and quantifying drug delivery in skin - Part 1: Autoradiography and mass spectrometry imaging. , 2019, Advanced drug delivery reviews.

[4]  Yousuf H. Mohammed,et al.  Using elongated microparticles to enhance tailorable nanoemulsion delivery in excised human skin and volunteers , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[5]  R. Boukherroub,et al.  Heat: A Highly Efficient Skin Enhancer for Transdermal Drug Delivery , 2018, Front. Bioeng. Biotechnol..

[6]  R. Neubert,et al.  Dermal and transdermal delivery of pharmaceutically relevant macromolecules , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  J. Rivers,et al.  Actikerall™ (5-Fluorouracil 0.5% and Salicylic Acid 10%) Topical Solution for Patient-directed Treatment of Actinic Keratoses. , 2016, Skin therapy letter.

[8]  M. Bentley,et al.  Chemical penetration enhancers. , 2015, Therapeutic delivery.

[9]  J. Simon,et al.  A prospective randomized exploratory study comparing the efficacy of once‐daily topical 0.5% 5‐fluorouracil in combination with 10.0% salicylic acid (5‐FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  T. Prow,et al.  Enhanced delivery of nano- and submicron particles using elongated microparticles. , 2015, Current drug delivery.

[11]  Richard H Guy,et al.  Transdermal drug delivery: 30+ years of war and still fighting! , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[12]  H. Soyer,et al.  High Aspect Ratio Elongated Microparticles for Enhanced Topical Drug Delivery in Human Volunteers , 2014, Advanced healthcare materials.

[13]  H. Wulf,et al.  Application of sunscreen − theory and reality , 2014, Photodermatology, photoimmunology & photomedicine.

[14]  H. Soyer,et al.  Elongate microparticles for enhanced drug delivery to ex vivo and in vivo pig skin. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[15]  J. Etzkorn,et al.  Topical and Intralesional Treatment of Nonmelanoma Skin Cancer: Efficacy and Cost Comparisons , 2013, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[16]  H. Maibach,et al.  Interindividual variation in transdermal and oral drug deliveries. , 2012, Journal of pharmaceutical sciences.

[17]  H. Kerl,et al.  Low‐dose 5‐fluorouracil in combination with salicylic acid as a new lesion‐directed option to treat topically actinic keratoses: histological and clinical study results , 2011, The British journal of dermatology.

[18]  A. Morris,et al.  Performance of transdermal therapeutic systems: Effects of biological factors , 2011, International journal of pharmaceutical investigation.

[19]  S. Culine,et al.  Inter- and Intraindividual Variabilities in Pharmacokinetics of Fentanyl After Repeated 72-Hour Transdermal Applications in Cancer Pain Patients , 2005, Therapeutic drug monitoring.

[20]  C. Schlagel,et al.  THE WEIGHTS OF TOPICAL PREPARATIONS REQUIRED FOR TOTAL AND PARTIAL BODY INUNCTION. , 1964, Journal of Investigative Dermatology.